ADGRF1

Adhesion G-protein coupled receptor F1 · Q5T601 · ADGRF1 on Sugi Atlas →

3,120 patent compounds predicted against ADGRF1, 2,561 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2594343	0.57	2/20
SCHEMBL2594863	0.53	2/20
SCHEMBL2594864	0.53	2/20
Bromide (SCHEMBL2584246)	0.41	2/20
SCHEMBL2595552	0.40	2/20
SCHEMBL2593678	0.36	2/20
SCHEMBL2593683	0.36	2/20
Salmeterol (SCHEMBL4767)	1.00	1/20
Salmeterol (SCHEMBL4768)	1.00	1/20
Loperamide (SCHEMBL15048)	1.00	1/20
SCHEMBL1315434	1.00	1/20
Hydrochloric Acid (SCHEMBL1878106)	1.00	1/20
Hydrochloric Acid (SCHEMBL2030327)	1.00	1/20
Hydrochloric Acid (SCHEMBL2240337)	1.00	1/20
Hydrochloric Acid (SCHEMBL2358624)	1.00	1/20
SCHEMBL1713111	0.99	1/20
SCHEMBL2360553	0.98	1/20
Hydrochloric Acid (SCHEMBL2860659)	0.98	1/20
SCHEMBL1843335	0.98	1/20
Loperamide (SCHEMBL2346867)	0.98	1/20

Clinical trials — most relevant to ADGRF1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer	PHASE2	COMPLETED
Phase II Dasatinib Study in Advanced Breast Cancer	PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations	PHASE1	COMPLETED
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS	PHASE1	UNKNOWN
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients	EARLY_PHASE1	UNKNOWN
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients	EARLY_PHASE1	COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke	EARLY_PHASE1	UNKNOWN
ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial	nan	UNKNOWN
Angiogenesis and Fibrosis in Aortic Stenosis	nan	COMPLETED
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors	nan	NOT_YET_RECRUITING
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation	nan	UNKNOWN
Angiogenesis and Fibrosis in Myocardial Infarction	nan	COMPLETED
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level	nan	COMPLETED
Thrombin Regulated Platelet Activation	nan	COMPLETED
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism.	nan	NOT_YET_RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
TIGIT in Patients With Chronic Myeloid Leukemia	nan	UNKNOWN
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation	nan	COMPLETED
Expression and Localization of FP Prostaglandin Receptor in Human Ocular Tissues	nan	UNKNOWN
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma	nan	UNKNOWN
Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients	nan	RECRUITING
The Effects of Sleeve Gastrectomy on Fractalkine	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ADGRF1 binder may also engage these)

Protein	Name	Similarity
Q8VEC3	—	0.998	Q8VEC3 →
Q9D2L6	—	0.994	Q9D2L6 →
D4A3T6	—	0.991	D4A3T6 →
Q8IZF3	—	0.989	Q8IZF3 →
Q8IZF7	—	0.988	Q8IZF7 →
Q7SY09	—	0.987	Q7SY09 →
Q9HBW9	—	0.987	Q9HBW9 →
Q8JZZ7	—	0.987	Q8JZZ7 →
Q9Z0M6	—	0.987	Q9Z0M6 →
ADGRE5	Adhesion G protein-coupled receptor E5	0.986	landscape →
E9Q4J9	—	0.985	E9Q4J9 →
Q9PW88	—	0.985	Q9PW88 →
Q9ESC1	—	0.985	Q9ESC1 →
Q8SQA4	—	0.985	Q8SQA4 →
O88923	—	0.984	O88923 →
E1BPQ3	—	0.984	E1BPQ3 →
Q9WVT0	—	0.983	Q9WVT0 →
Q59I63	—	0.983	Q59I63 →
Q923X1	—	0.983	Q923X1 →
O95490	—	0.982	O95490 →
O97817	—	0.982	O97817 →
O88917	—	0.981	O88917 →
Q00PJ8	—	0.981	Q00PJ8 →
G5E8Q8	—	0.981	G5E8Q8 →
CASR	Extracellular calcium-sensing receptor	0.981	landscape →
Q60629	—	0.981	Q60629 →
O94910	—	0.980	O94910 →
Q8CF82	—	0.980	Q8CF82 →
A0M8R7	—	0.980	A0M8R7 →
Q9HAR2	—	0.979	Q9HAR2 →